Clearside Biomedical (CLSD)
(Real Time Quote from BATS)
$1.28 USD
+0.05 (4.07%)
Updated May 14, 2024 01:28 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
CLSD 1.28 +0.05(4.07%)
Will CLSD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLSD
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates
Other News for CLSD
Buy Rating for Clearside Biomedical Amid Promising CLS-AX Trial Progress and Sufficient Cash Runway
Clearside Biomedical price target lowered by $1 at H.C. Wainwright, here's why
Buy Rating Affirmed: Clearside Biomedical’s Promising Phase 2b Odyssey Trial and Strategic CMO Hire Signal Strong Outlook
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
Buy Rating on Clearside Biomedical: Anticipating ODYSSEY Trial Success and Market Growth Potential